Circulating Tumor Cells Advances in Liquid Biopsy Technologies /
It is well recognized that blood could be the optimal site for evaluating cancer, allowing easy and repeated access for determining prognosis, establishing molecular targets, evaluating the efficacy of therapy, detecting the earliest signs of recurrence, and even detecting cancer at its earliest and...
محفوظ في:
| مؤلف مشترك: | |
|---|---|
| مؤلفون آخرون: | , |
| التنسيق: | الكتروني كتاب الكتروني |
| اللغة: | الإنجليزية |
| منشور في: |
Cham :
Springer International Publishing : Imprint: Springer,
2023.
|
| الطبعة: | 2nd ed. 2023. |
| سلاسل: | Current Cancer Research,
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1007/978-3-031-22903-9 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
MARC
| LEADER | 00000nam a22000005i 4500 | ||
|---|---|---|---|
| 001 | 978-3-031-22903-9 | ||
| 003 | DE-He213 | ||
| 005 | 20251113195814.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 230801s2023 sz | s |||| 0|eng d | ||
| 020 | |a 9783031229039 |9 978-3-031-22903-9 | ||
| 024 | 7 | |a 10.1007/978-3-031-22903-9 |2 doi | |
| 050 | 4 | |a RC261-271 | |
| 072 | 7 | |a MJCL |2 bicssc | |
| 072 | 7 | |a MED062000 |2 bisacsh | |
| 072 | 7 | |a MJCL |2 thema | |
| 082 | 0 | 4 | |a 571.978 |2 23 |
| 082 | 0 | 4 | |a 616.994 |2 23 |
| 245 | 1 | 0 | |a Circulating Tumor Cells |h [electronic resource] : |b Advances in Liquid Biopsy Technologies / |c edited by Richard J. Cote, Evi Lianidou. |
| 250 | |a 2nd ed. 2023. | ||
| 264 | 1 | |a Cham : |b Springer International Publishing : |b Imprint: Springer, |c 2023. | |
| 300 | |a XXI, 668 p. 77 illus., 72 illus. in color. |b online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 341 | 0 | |b Table of contents navigation |2 onix | |
| 341 | 0 | |b Single logical reading order |2 onix | |
| 341 | 0 | |b Short alternative textual descriptions |2 onix | |
| 341 | 0 | |b Use of color is not sole means of conveying information |2 onix | |
| 341 | 0 | |b Use of high contrast between text and background color |2 onix | |
| 341 | 0 | |b Next / Previous structural navigation |2 onix | |
| 341 | 0 | |b All non-decorative content supports reading without sight |2 onix | |
| 347 | |a text file |b PDF |2 rda | ||
| 490 | 1 | |a Current Cancer Research, |x 2199-2592 | |
| 505 | 0 | |a Part 1. CTC Technologies -- Affinity -- Physical -- ctDNA -- miRNA -- Exosomes -- Part 2 -- Biology of CTC -- Dormancy -- Culture -- EMT -- ctDNA and Exosomes -- Cells in circulation with CTC -- Part 3 -- CTC Analysis -- IHC, FISH, and other molecular assays -- Functional characterization -- Advanced microscopy and AI -- Analysis of non-cellular circulating markers -- Part 4 -- Clinical Applications of the Liquid Biopsy -- Early detection and cancer screening -- Prognosis and therapeutic monitoring -- Applications in Clinical Trials -- Applications in Drug Development. | |
| 520 | |a It is well recognized that blood could be the optimal site for evaluating cancer, allowing easy and repeated access for determining prognosis, establishing molecular targets, evaluating the efficacy of therapy, detecting the earliest signs of recurrence, and even detecting cancer at its earliest and most curable stages. The analysis of cancer through blood samples is now known as the liquid biopsy and has been a rich source of research and clinical application. There has been an explosion of interest and progress in liquid biopsy technologies since the first edition of this book. The second edition will expand its focus to now include not only circulating tumor cells (CTC), but also other emerging aspects of the liquid biopsy, including circulating tumor DNA and methylated DNA (ctDNA, ct meDNA), ctRNA, ct miRNA, circulating tumor proteins (and other) biomarkers and circulating tumor derived exosomes (ctExosomes). | ||
| 532 | 8 | |a Accessibility summary: This PDF does not fully comply with PDF/UA standards, but does feature limited screen reader support, described non-text content (images, graphs), bookmarks for easy navigation and searchable, selectable text. Users of assistive technologies may experience difficulty navigating or interpreting content in this document. We recognize the importance of accessibility, and we welcome queries about accessibility for any of our products. If you have a question or an access need, please get in touch with us at accessibilitysupport@springernature.com. | |
| 532 | 8 | |a No reading system accessibility options actively disabled | |
| 532 | 8 | |a Publisher contact for further accessibility information: accessibilitysupport@springernature.com | |
| 650 | 0 | |a Cancer. | |
| 650 | 0 | |a Cancer |x Treatment. | |
| 650 | 0 | |a Tumor markers. | |
| 650 | 1 | 4 | |a Cancer Biology. |
| 650 | 2 | 4 | |a Cancer Therapy. |
| 650 | 2 | 4 | |a Tumour Biomarkers. |
| 700 | 1 | |a Cote, Richard J. |e editor. |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 700 | 1 | |a Lianidou, Evi. |e editor. |0 (orcid)0000-0002-7796-5914 |1 https://orcid.org/0000-0002-7796-5914 |4 edt |4 http://id.loc.gov/vocabulary/relators/edt | |
| 710 | 2 | |a SpringerLink (Online service) | |
| 773 | 0 | |t Springer Nature eBook | |
| 776 | 0 | 8 | |i Printed edition: |z 9783031229022 |
| 776 | 0 | 8 | |i Printed edition: |z 9783031229046 |
| 830 | 0 | |a Current Cancer Research, |x 2199-2592 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-031-22903-9 |
| 912 | |a ZDB-2-SBL | ||
| 912 | |a ZDB-2-SXB | ||
| 950 | |a Biomedical and Life Sciences (SpringerNature-11642) | ||
| 950 | |a Biomedical and Life Sciences (R0) (SpringerNature-43708) | ||